14 September 2021 - Zepzelca approval granted under a provisional regulatory pathway.
Australian patients with an aggressive form of lung cancer (metastatic small cell lung cancer) can now access a new therapy that may improve outcomes.
The therapy, Zepzelca (lurbinectedin) has been approved by the Therapeutic Goods Administration "for the treatment of patients with metastatic small cell lung cancer that has progressed on or after prior platinum-containing therapy".